(Reuters) - A study published in the New England Journal of Medicine said Avandia increased the risk of cardiac-related deaths by 64 percent and heart attacks by 43 percent. Dr. Robert Meyer, head of the FDA office that reviews diabetes drugs, said other data contradicted those findings.
"FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies," Meyer told reporters during a conference call.
Read more at Reuters.com Business News
"FDA has not confirmed the clinical significance of the reported increased risk in the context of other studies," Meyer told reporters during a conference call.
Read more at Reuters.com Business News
No comments:
Post a Comment